Diagnostic Efficacy and Clinical Significance of Lymphocyte Subsets, Granzyme B and Perforin in the Peripheral Blood of Patients with Invasive Breast Cancer Following Neoadjuvant Chemotherapy
Authors:
Open Access
- 1 March 2025
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 589-602
Abstract
Purpose: Breast cancer, a predominant contributor to cancer-related mortality worldwide, is increasingly managed through the application of neoadjuvant chemotherapy (NAC). Analyzing the dynamic changes in peripheral blood lymphocyte subsets, granzyme B and perforin are crucial for investigating their roles in tumorigenesis, development and treatment; this study aimed to use these analyses to diagnose malignant breast tumor, assess the anti-tumor immunity and predict chemotherapy efficacy in breast cancer patients. Patients and Methods: To address this objective, a total of 582 peripheral blood samples were collected from healthy controls (n=47), benign breast disease patients (n=401) and breast cancer patients (n=134). Lymphocyte subsets, along with granzyme B and perforin expression, were assessed using flow cytometry. Changes before and after NAC were also monitored. Results: Breast cancer patients exhibited reduced proportions and absolute counts of CD3+ and CD8+ T cells, increased NK cell percentage and CD4+/CD8+ ratio, and higher levels of granzyme B and perforin in CD3+, CD8+ T cells and NK cells. Post-NAC, the percentages of CD3+, CD4+, CD8+ T cells and NK cells increased, along with a higher CD4+/CD8+ ratio, while B cell percentages decreased compared to pre-NAC. Furthermore, the effective group showed higher percentages of CD3+, CD8+ T cells and lower percentages of B cells than the ineffective group post-NAC. Incidentally, Granzyme B and perforin expression in CD3+ and CD8+ T cells was elevated following postoperative chemotherapy. Conclusion: These findings indicated that peripheral blood lymphocyte subsets, along with granzyme B and perforin levels, could serve as potential biomarkers for differentiating benign from malignant breast tumors, assessing anti-tumor immunity and predicting chemotherapy efficacy.Keywords
This publication has 56 references indexed in Scilit:
- Diagnostic and prognostic value of double-negative T cells in colorectal cancerHeliyon, 2024
- CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgeryJournal of Cachexia, Sarcopenia and Muscle, 2024
- Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancerImmunity, Inflammation and Disease, 2024
- Deciphering breast cancer: from biology to the clinicCell, 2023
- B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunityCancer Cell, 2023
- Breast cancer immunotherapy: Current and novel approachesInternational Immunopharmacology, 2021
- The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patientsHepatology International, 2021
- The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLCLung Cancer, 2019
- Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implicationsInternational Journal of Cancer, 2017
- Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administrationSeminars in Cancer Biology, 2003